Search results
Results from the WOW.Com Content Network
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. [8] [9] In CLL, the bone marrow makes too many lymphocytes, which are a type of white blood cell. [8] [9] In patients with CLL, B cell lymphocytes can begin to collect in their blood, spleen, lymph nodes, and bone marrow.
Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). [7] For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used.
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. [8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. [8] It is given by injection into a vein. [8]
Treatment of adults with newly diagnosed Philadelphia chromosomepositive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) [2] Blinatumomab Treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in people aged one month of age ...
Treatment can occasionally consist of "watchful waiting" (e.g., in CLL) or symptomatic treatment (e.g., blood transfusions in MDS). The more aggressive forms of disease require treatment with chemotherapy, radiotherapy, immunotherapy and—in some cases—a bone marrow transplant.
Specialty: Hematology and oncology: Symptoms: Bleeding, bruising, fatigue, fever, increased risk of infections [2] Usual onset: All ages, [3] most common in 60s and 70s. [4] It is the most common malignant cancer in children, but the cure rates are also higher for them.
Since McAllister's 1997 report on a patient with multiple sclerosis (MS) who received a bone-marrow transplant for chronic myelogenous leukemia (CML), [88] over 600 reports have been published describing HSCTs performed primarily for MS. [89] These have been shown to "reduce or eliminate ongoing clinical relapses, halt further progression, and ...
This occurs most commonly after the treatment of lymphomas and leukemias and in particular when treating non-Hodgkin lymphoma, acute myeloid leukemia, and acute lymphoblastic leukemia. [ 2 ] [ 3 ] This is a potentially fatal complication and people at an increased risk for TLS should be closely monitored while receiving chemotherapy and should ...